BioReperia offers a technology used to accelerate drug discovery, but also in clinical studies to test individual treatments on specific patients. Many drugs fail in the later stages of development due to efficacy issues. The first product from BioReperia, originating from the medical faculty and departments HMV and BKV at Linköping University, accelerates the assessment of drug effect through early proof-of-concept studies in toxicology, oncology and for personalized cancer medicine through the use of xenograft zebrafish models. BioReperia’s overall goal is to minimize suffering and mortality caused by cancer and other diseases, something that the product contributes to.